Medpace (MEDP)
(Delayed Data from NSDQ)
$390.91 USD
+4.59 (1.19%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $390.50 -0.41 (-0.10%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth B Momentum B VGM
Medpace (MEDP) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$414.63 | $435.00 | $336.00 | 7.33% |
Price Target
Based on short-term price targets offered by eight analysts, the average price target for Medpace comes to $414.63. The forecasts range from a low of $336.00 to a high of $435.00. The average price target represents an increase of 7.33% from the last closing price of $386.32.
Analyst Price Targets (8 )
Broker Rating
Medpace currently has an average brokerage recommendation (ABR) of 1.44 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by nine brokerage firms. The current ABR compares to an ABR of 1.25 a month ago based on eight recommendations.
Of the nine recommendations deriving the current ABR, seven are Strong Buy, representing 77.78% of all recommendations. A month ago, Strong Buy represented 87.5%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/MEDP.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 7 | 7 | 7 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.44 | 1.44 | 1.25 | 1.25 | 1.25 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/1/2024 | Truist Securities | Jailendra Singh | Hold | Hold |
7/24/2024 | Robert W. Baird & Co. | Eric W Coldwell | Strong Buy | Strong Buy |
7/24/2024 | Cowen & Co. | Charles Rhyee | Strong Buy | Strong Buy |
7/24/2024 | UBS | John N Sourbeer | Strong Buy | Strong Buy |
7/24/2024 | Guggenheim Securities | Jack D Wallace | Strong Buy | Strong Buy |
7/23/2024 | William Blair | Maxwell A Smock | Strong Buy | Strong Buy |
5/28/2024 | Mizuho SecuritiesUSA | Ann K Hynes | Not Available | Strong Buy |
4/23/2024 | Not Identified | Not Identified | Hold | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.44 |
ABR (Last week) | 1.44 |
# of Recs in ABR | 9 |
Average Target Price | $414.63 |
LT Growth Rate | 16.50% |
Industry | Medical Services |
Industry Rank by ABR | 148 of 253 |
Current Quarter EPS Est: | 2.78 |